XML 52 R40.htm IDEA: XBRL DOCUMENT
v3.20.4

Business Segments (Tables) | 9 Months Ended
--- | ---
Dec. 31, 2020
Segment Reporting [Abstract] |
Information about our Operating and Reportable Segments | The tables below summarize information about our reportable segments.
| Three Months Ended December 31, 2020
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Total segment revenues* | $ | 210,618 |  |  | $ | 28,170 |  |  |  |  | $ | 238,788 |
Cost of sales | 88,883 |  |  | 11,018 |  |  |  |  | 99,901 |
Gross profit | 121,735 |  |  | 17,152 |  |  |  |  | 138,887 |
Advertising and marketing | 32,859 |  |  | 5,222 |  |  |  |  | 38,081 |
Contribution margin | $ | 88,876 |  |  | $ | 11,930 |  |  |  |  | 100,806 |
Other operating expenses |  |  |  |  |  |  | 27,363 |
Operating income |  |  |  |  |  |  | $ | 73,443 |
* Intersegment revenues of $0.8 million were eliminated from the North American OTC Healthcare segment.
| Nine Months Ended December 31, 2020
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Total segment revenues* | $ | 637,851 |  |  | $ | 67,753 |  |  |  |  | $ | 705,604 |
Cost of sales | 267,779 |  |  | 27,409 |  |  |  |  | 295,188 |
Gross profit | 370,072 |  |  | 40,344 |  |  |  |  | 410,416 |
Advertising and marketing | 91,553 |  |  | 12,619 |  |  |  |  | 104,172 |
Contribution margin | $ | 278,519 |  |  | $ | 27,725 |  |  |  |  | 306,244 |
Other operating expenses |  |  |  |  |  |  | 79,779 |
Operating income |  |  |  |  |  |  | $ | 226,465 |
* Intersegment revenues of $2.4 million were eliminated from the North American OTC Healthcare segment.
| Three Months Ended December 31, 2019
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Total segment revenues* | $ | 214,892 |  |  | $ | 26,660 |  |  |  |  | $ | 241,552 |
Cost of sales | 93,937 |  |  | 10,120 |  |  |  |  | 104,057 |
Gross profit | 120,955 |  |  | 16,540 |  |  |  |  | 137,495 |
Advertising and marketing | 29,025 |  |  | 4,534 |  |  |  |  | 33,559 |
Contribution margin | $ | 91,930 |  |  | $ | 12,006 |  |  |  |  | 103,936 |
Other operating expenses |  |  |  |  |  |  | 27,532 |
Operating income |  |  |  |  |  |  | $ | 76,404 |
* Intersegment revenues of $0.6 million were eliminated from the North American OTC Healthcare segment.
| Nine Months Ended December 31, 2019
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Total segment revenues* | $ | 639,554 |  |  | $ | 72,221 |  |  |  |  | $ | 711,775 |
Cost of sales | 275,679 |  |  | 27,783 |  |  |  |  | 303,462 |
Gross profit | 363,875 |  |  | 44,438 |  |  |  |  | 408,313 |
Advertising and marketing | 94,634 |  |  | 12,393 |  |  |  |  | 107,027 |
Contribution margin | $ | 269,241 |  |  | $ | 32,045 |  |  |  |  | 301,286 |
Other operating expenses |  |  |  |  |  |  | 84,048 |
Operating income |  |  |  |  |  |  | $ | 217,238 |
* Intersegment revenues of $2.1 million were eliminated from the North American OTC Healthcare segment.
Information about our Revenues from Similar Product Groups | The tables below summarize information about our segment revenues from similar product groups.
| Three Months Ended December 31, 2020 |
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated |
Analgesics | $ | 29,427 |  |  | $ | 423 |  |  |  |  | $ | 29,850 |  |
Cough & Cold | 16,871 |  |  | 3,877 |  |  |  |  | 20,748 |  |
Women's Health | 60,257 |  |  | 4,229 |  |  |  |  | 64,486 |  |
Gastrointestinal | 31,886 |  |  | 13,436 |  |  |  |  | 45,322 |  |
Eye & Ear Care | 23,166 |  |  | 2,326 |  |  |  |  | 25,492 |  |
Dermatologicals | 24,602 |  |  | 791 |  |  |  |  | 25,393 |  |
Oral Care | 22,907 |  |  | 3,086 |  |  |  |  | 25,993 |  |
Other OTC | 1,502 |  |  | 2 |  |  |  |  | 1,504 |  |
Total segment revenues | $ | 210,618 |  |  | $ | 28,170 |  |  |  |  | $ | 238,788 |  |
| Nine Months Ended December 31, 2020
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Analgesics | $ | 87,917 |  |  | $ | 964 |  |  |  |  | $ | 88,881 |
Cough & Cold | 45,105 |  |  | 10,865 |  |  |  |  | 55,970 |
Women's Health | 187,159 |  |  | 10,766 |  |  |  |  | 197,925 |
Gastrointestinal | 93,654 |  |  | 25,520 |  |  |  |  | 119,174 |
Eye & Ear Care | 72,785 |  |  | 7,908 |  |  |  |  | 80,693 |
Dermatologicals | 80,097 |  |  | 2,326 |  |  |  |  | 82,423 |
Oral Care | 67,017 |  |  | 9,399 |  |  |  |  | 76,416 |
Other OTC | 4,117 |  |  | 5 |  |  |  |  | 4,122 |
Total segment revenues | $ | 637,851 |  |  | $ | 67,753 |  |  |  |  | $ | 705,604 |
| Three Months Ended December 31, 2019
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Analgesics | $ | 28,330 |  |  | $ | 175 |  |  |  |  | $ | 28,505 |
Cough & Cold | 25,221 |  |  | 4,742 |  |  |  |  | 29,963 |
Women's Health | 58,576 |  |  | 3,543 |  |  |  |  | 62,119 |
Gastrointestinal | 32,645 |  |  | 12,097 |  |  |  |  | 44,742 |
Eye & Ear Care | 24,095 |  |  | 3,159 |  |  |  |  | 27,254 |
Dermatologicals | 23,286 |  |  | 598 |  |  |  |  | 23,884 |
Oral Care | 21,451 |  |  | 2,344 |  |  |  |  | 23,795 |
Other OTC | 1,288 |  |  | 2 |  |  |  |  | 1,290 |
Total segment revenues | $ | 214,892 |  |  | $ | 26,660 |  |  |  |  | $ | 241,552 |
| Nine Months Ended December 31, 2019
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Analgesics | $ | 85,696 |  |  | $ | 648 |  |  |  |  | $ | 86,344 |
Cough & Cold | 63,067 |  |  | 15,938 |  |  |  |  | 79,005 |
Women's Health | 177,832 |  |  | 8,867 |  |  |  |  | 186,699 |
Gastrointestinal | 96,431 |  |  | 28,110 |  |  |  |  | 124,541 |
Eye & Ear Care | 73,134 |  |  | 9,355 |  |  |  |  | 82,489 |
Dermatologicals | 77,063 |  |  | 1,864 |  |  |  |  | 78,927 |
Oral Care | 62,493 |  |  | 7,435 |  |  |  |  | 69,928 |
Other OTC | 3,838 |  |  | 4 |  |  |  |  | 3,842 |
Total segment revenues | $ | 639,554 |  |  | $ | 72,221 |  |  |  |  | $ | 711,775 |
Information about our Segment Revenues by Geographic Area | Our total segment revenues by geographic area are as follows:
| Three Months Ended December 31, |  | Nine Months Ended December 31,
| 2020 |  | 2019 |  | 2020 |  | 2019
United States | $ | 197,296 |  |  | $ | 203,920 |  |  | $ | 599,931 |  |  | $ | 604,263 |
Rest of world | 41,492 |  |  | 37,632 |  |  | 105,673 |  |  | 107,512 |
Total | $ | 238,788 |  |  | $ | 241,552 |  |  | $ | 705,604 |  |  | $ | 711,775 |
Information about our Consolidated Goodwill and Intangible Assets Allocated to Reportable Segments | Our consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:
December 31, 2020 | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
(In thousands) |  |  |  |  |  |  |
Goodwill | $ | 546,643 |  |  | $ | 32,916 |  |  |  |  | $ | 579,559 |
Intangible assets |  |  |  |  |  |  |
Indefinite-lived | 2,195,617 |  |  | 87,514 |  |  |  |  | 2,283,131 |
Finite-lived, net | 195,248 |  |  | 3,346 |  |  |  |  | 198,594 |
Intangible assets, net | 2,390,865 |  |  | 90,860 |  |  |  |  | 2,481,725 |
Total | $ | 2,937,508 |  |  | $ | 123,776 |  |  |  |  | $ | 3,061,284 |
March 31, 2020 | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
(In thousands) |  |  |  |  |  |  |
Goodwill | $ | 546,643 |  |  | $ | 28,536 |  |  |  |  | $ | 575,179 |
Intangible assets |  |  |  |  |  |  |
Indefinite-lived | 2,195,617 |  |  | 69,714 |  |  |  |  | 2,265,331 |
Finite-lived, net | 209,604 |  |  | 4,456 |  |  |  |  | 214,060 |
Intangible assets, net | 2,405,221 |  |  | 74,170 |  |  |  |  | 2,479,391 |
Total | $ | 2,951,864 |  |  | $ | 102,706 |  |  |  |  | $ | 3,054,570 |

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 + Details
Name: | us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph a -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration